4D Molecular Therapeutics (FDMT) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Valneva (VALN) over the past year, losing 5.6% versus a loss of 40.1%. Over five years, FDMT leads with a -53.6% price change compared with -91.3% for VALN. 4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $490.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | VALN |
|---|---|---|
| Share price | $10.23 | $5.16 |
| Market cap | $576.76M | $490.86M |
| 1-day change | -4.57% | -3.82% |
| YTD return | +36.40% | -41.50% |
| 1-year return | -5.63% | -40.14% |
| 5-year return | -53.61% | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-2.70 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.21M | — |
| Revenue growth (YoY) | +230194.59% | — |
| Net income (latest FY) | $-140.11M | — |
| Operating margin | -187.24% | — |
| Net margin | -164.43% | — |
| 52-week high | $16.93 | $12.18 |
| 52-week low | $6.96 | $4.75 |
| Distance from 52-week high | -39.57% | -57.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +174.58% | +137.98% |
| Average volume | 967.00K | 23.10K |
| Shares outstanding | 56.38M | 95.13M |
| Employees | 196 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed VALN by 34.5 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
FDMT vs VALN FAQ
Which is bigger, 4D Molecular Therapeutics or Valneva?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $490.86M for Valneva (VALN).
Which stock has performed better over the past year, FDMT or VALN?
FDMT returned -5.63% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.